Whitehawk Therapeutics, Inc. (WHWK)

NCM – Real Time Price. Currency in USD

4.16

+0.05 (1.22%)

At close: Jun 26, 2026, 4:00 PM EDT

4.16

-0.00 (-0.00%)

After-hours: Jun 26, 2026, 4:31 PM EDT

30.05.2026

Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026

SEZ6 expression exceeds that of approved and emerging ADC targets in SCLC SEZ6 expression is positively correlated with DLL3 expression across neuroendocrine carcinomas, indicating potential for combination Findings support Whitehawk's development of SEZ6-directed ADC, HWK-206, with an IND submission expected mid-2026 MORRISTOWN, N.J., May 30, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced the presentation of a real world analysis supporting the therapeutic potential of targeting seizure related homolog protein 6 (SEZ6) with a next-generation ADC for the treatment of neuroendocrine tumors, including small cell lung cancer (SCLC).

28.05.2026

Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference

MORRISTOWN, N.J., May 28, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced Dave Lennon, PhD, President and CEO, will present at the Jefferies 2026 Global Healthcare Conference in New York City, NY on Thursday, June 4 at 8:10 AM ET.

21.05.2026

Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload

Agreement with Hangzhou DAC Provides Option for Up to Five New, Internally Developed ADC Programs, Including Dual-Payload Variations Hangzhou DAC's DXC006 Data at ASCO Reinforce Conviction for CPT113, a Core Technology of Whitehawk's ADC Platform Phase 1 Dose-Escalation Trials of HWK-007 and HWK-016 are Currently Enrolling; HWK-007 Trials-in-Progress Poster to be Presented at ASCO MORRISTOWN, N.J., May 21, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced it entered into a new option agreement with Hangzhou DAC for access to CPT113 for use in up to five additional ADC programs.

20.05.2026

Whitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation Summit

MORRISTOWN, N.J., May 20, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced Dave Lennon, PhD, President and CEO, will participate in a virtual fireside chat as part of the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA on Wednesday, May 27, 2026, at 11:00 AM ET.

15.05.2026

Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum

MORRISTOWN, N.J., May 15, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced Dave Lennon, PhD, President and CEO, will participate in a virtual fireside chat as part of the 2026 Stifel Virtual Targeted Oncology Forum on Tuesday, May 19, 2026, at 3 PM ET.

15.05.2026

Whitehawk Therapeutics: 'Hold' On Name Change And Next Generation PTK7 ADC Targeting

Whitehawk Therapeutics pivots to focus on three next-generation antibody-drug conjugates [ADCs] after selling FYARRO and rebranding from Aadi Bioscience. I downgrade WHWK from 'Strong Buy' to 'Hold' due to the early-stage pipeline, competitive landscape, and unproven efficacy/safety of modified ADCs. Key catalysts include phase 1 data readouts for HWK-007 and HWK-016 in 1H 2027 and an IND filing for HWK-206 in mid-2026.

13.05.2026

Whitehawk Therapeutics Announces $87.5M Private Placement Equity Financing

MORRISTOWN, N.J., May 13, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (the "Company" or "Whitehawk") (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced that it has entered into a securities purchase agreement with certain qualified institutional buyers and accredited investors for a private investment in public equity ("PIPE") financing that is expected to result in gross proceeds of approximately $87.5 million, before deducting placement agent fees and other private placement expenses.

Videos

No Data

There is no data to display

Press releases

30.05.2026

Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026

21.05.2026

Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload

20.05.2026

Whitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation Summit

15.05.2026

Whitehawk Therapeutics, Inc. (WHWK)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Whitehawk Therapeutics, Inc. (WHWK)

Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026

Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference

Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload

Whitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation Summit

Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum

Whitehawk Therapeutics: 'Hold' On Name Change And Next Generation PTK7 ADC Targeting

Whitehawk Therapeutics Announces $87.5M Private Placement Equity Financing

Videos

No Data

Press releases

Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026

Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload

Whitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation Summit

Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum

Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026

Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference

Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload

Whitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation Summit

Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum

Whitehawk Therapeutics: 'Hold' On Name Change And Next Generation PTK7 ADC Targeting

Whitehawk Therapeutics Announces $87.5M Private Placement Equity Financing

Videos

No Data

Press releases

Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026

Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload

Whitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation Summit

Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum

Search stocks

Whitehawk Therapeutics, Inc. (WHWK)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Whitehawk Therapeutics, Inc. (WHWK)

Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026

Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference

Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload

Whitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation Summit

Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum

Whitehawk Therapeutics: 'Hold' On Name Change And Next Generation PTK7 ADC Targeting

Whitehawk Therapeutics Announces $87.5M Private Placement Equity Financing

Videos

No Data

Press releases

Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026

Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload

Whitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation Summit

Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum

Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026

Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference

Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload

Whitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation Summit

Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum

Whitehawk Therapeutics: 'Hold' On Name Change And Next Generation PTK7 ADC Targeting

Whitehawk Therapeutics Announces $87.5M Private Placement Equity Financing

Videos

No Data

Press releases

Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026

Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload

Whitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation Summit

Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum